Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMD2GKF)

• Drug Name: SFLT-01 Drug Info
• Synonyms: AAV2-sFLT-01; VEGF/PIGF suppression gene therapy (cancer), Genzyme; SFLT-01 gene therapy (wet AMD), AGTC/Genzyme; VEGF suppression gene therapy (wet age-related macular degeneration), Applied Genetic Technologies/ Genzyme

Indication

Disease Entry	ICD 11	Status	REF
Macular degeneration	9B78.3	Phase 1	[1]

• Cross-matching ID: TTD Drug ID: DMD2GKF

Molecule-Related Drug Atlas

Drug(s) Targeting Vascular endothelial growth factor A (VEGFA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[3]
Brolucizumab	DMW8QNG	Wet age-related macular degeneration	9B78.3Z	Approved	[4]
Faricimab	DM83SEB	Diabetic macular edema	9B71.02	Approved	[5]
Ranibizumab	DMSYPNW	Central retinal vein occlusion with macular edema		Approved	[6]
Bevacizumab	DMSD1UN	Adenocarcinoma	2D40	Approved	[7]
Avastin+/-Tarceva	DMA86FL	Non-small-cell lung cancer	2C25.Y	Phase 3	[8]
PTC299	DMP9TKE	Rheumatoid arthritis	FA20	Phase 2	[9]
RG7221	DM8J9DC	Colorectal cancer	2B91.Z	Phase 2	[10]
RO5520985	DMD3WNP	Colorectal cancer	2B91.Z	Phase 2	[11]
Abicipar pegol	DM59OJ2	Diabetic macular edema	9B71.02	Phase 2	[12]

Drug(s) Targeting Placenta growth factor (PlGF)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aflibercept	DMT3D5I	Central retinal vein occlusion with macular edema		Approved	[3]
RO-5323441	DMUB3OY	Solid tumour/cancer	2A00-2F9Z	Phase 2	[13]
TB-403	DMDPBMH	Glioblastoma of brain	2A00.00	Phase 2	[14]
R7334	DMVA186	Macular degeneration	9B78.3	Phase 1	[15]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[16]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Placenta growth factor (PlGF)	TT48I1Y	PLGF_HUMAN	Modulator	[2]
Vascular endothelial growth factor A (VEGFA)	TTOHSBA	VEGFA_HUMAN	Modulator	[2]

References

• [1] ClinicalTrials.gov (NCT01024998) Safety and Tolerability Study of AAV2-sFLT01 in Patients With Neovascular Age-Related Macular Degeneration (AMD). U.S. National Institutes of Health.
• [2] sFLT01: a novel fusion protein with antiangiogenic activity. Mol Cancer Ther. 2011 Mar;10(3):404-15.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [5] Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases. Expert Opin Investig Drugs. 2021 Mar;30(3):193-200.
• [6] Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina. 2006 Oct;26(8):859-70.
• [7] FDA Approved Drug Products from FDA Official Website. 2004. Application Number: (ANDA) 125085.
• [8] Clinical pipeline report, company report or official report of Genentech (2009).
• [9] Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study.J Neurooncol.2015 Jan;121(1):217-24.
• [10] Bispecific antibodies and their applications
• [11] Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801.
• [12] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [13] RO5323441, a humanized monoclonal antibody against the placenta growth factor, blocks PlGF-induced VEGFR-1 phosphorylation in vitro and tumor growth in vivo. Cancer Research. 01/2011.
• [14] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [15] Clinical pipeline report, company report or official report of Roche (2009).
• [16] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.